CollabRx

CollabRx, Inc. was a United States healthcare technology company focused on applying computational methods and expert medical knowledge to personalized medicine. Its principal concept was a cloud-based decision-support system for molecular diseases, especially cancer. The company sought to help clinicians and diagnostic laboratories interpret patient-specific molecular or genomic findings and connect those findings with potentially relevant treatment options. The platform was built around dynamically maintained molecular disease models. Rather than treating a genetic test result as an isolated data point, the system was intended to organize biological findings, disease mechanisms, clinical evidence, and therapeutic approaches into a structured knowledge base. This approach addressed a central problem in precision medicine: the rapid expansion of biological and clinical information made it difficult for individual practitioners to identify which findings were actionable for a particular patient. CollabRx’s software was designed to distill that information into treatment-oriented guidance. The knowledge bases supporting the company’s models were informed and updated by a network of advisers associated with academic and medical institutions. The company’s technology therefore combined software development with a collaborative knowledge-management process. Its commercial model was based on software-as-a-service access to the expert systems rather than on the sale of a conventional packaged diagnostic product. A major prospective customer group was DNA testing laboratories. These laboratories increasingly generated patient-specific molecular profiles but needed tools that could translate laboratory results into clinically useful treatment information. CollabRx positioned its systems as a bridge between molecular characterization and therapeutic decision-making, particularly for complex or genetically heterogeneous cancers. The company was founded in 2008 by computer scientist Jeff Shrager, Silicon Valley internet entrepreneur Jay Martin Tenenbaum, and mathematician Raphael Lehrer. In July 2012, Tegal Corporation acquired CollabRx. In October 2015, CollabRx was merged with Medytox Solutions. The available reference material does not document an independent operating business after that merger, and the brand is treated here as defunct. No current website, operating leadership, public ticker, or independently reported financial information is identified in the supplied sources.

CollabRx emerged during the development of precision medicine, a period in which genomic testing and molecular biology were producing rapidly increasing quantities of information about disease and treatment. The company was founded in 2008 by Jeff Shrager, a computer scientist; Jay Martin Tenenbaum, an internet entrepreneur associated with Silicon Valley; and Raphael Lehrer, a mathematician. Their concept was to develop software capable of turning complex molecular-disease information into clinically useful treatment guidance. The company’s technology centered on cloud-based expert systems. These systems used dynamically updated molecular disease models as the underlying framework for analyzing disease biology and identifying treatment approaches. The models were supported by knowledge bases that drew on contributions and review from a broad advisory network linked to academic and medical institutions. This collaborative structure was intended to keep the system aligned with evolving scientific and clinical evidence rather than relying on a static database. CollabRx focused particularly on cancer and other diseases in which molecular characteristics can influence treatment selection. The company addressed the gap between laboratory testing and clinical action: a DNA or molecular test can identify mutations, alterations, or other biological features, but those findings still need to be interpreted in the context of disease mechanisms, available therapies, clinical evidence, and the patient’s treatment situation. CollabRx’s expert systems were designed to help organize those relationships and make the resulting information accessible to healthcare decision-makers. Access to the systems was offered through software-as-a-service contracts. This model allowed users to access the company’s continually maintained knowledge and analytical functions through hosted software instead of installing a fixed product locally. DNA testing laboratories were identified as an important potential customer group because such laboratories needed ways to convert patient-specific genetic characterization into patient-specific clinical treatment advice. The company therefore occupied an intermediary position between genomic diagnostics, medical knowledge management, and clinical decision support. In July 2012, Tegal Corporation acquired CollabRx. The acquisition marked a significant corporate transition for the business, although the supplied reference material does not describe the transaction’s financial terms or provide detailed information about changes to the product portfolio. In October 2015, CollabRx was merged with Medytox Solutions. Available reference material does not establish that CollabRx continued as an independent operating brand after that merger. Accordingly, it is recorded as defunct, with no verified current website, leadership team, listed ticker, or independently reported financial profile in the available sources.

• 2015

  Merger with Medytox Solutions

  [1]CollabRxen.wikipedia.org

  CollabRx merged with Medytox Solutions in October 2015, ending the documented period of CollabRx as an independent company.

• 2012

  Acquisition by Tegal Corporation

  [1]CollabRxen.wikipedia.org

  Tegal Corporation acquired CollabRx in July 2012.

• 2008

  CollabRx is founded

  [1]CollabRxen.wikipedia.org

  Jeff Shrager, Jay Martin Tenenbaum, and Raphael Lehrer founded CollabRx to develop computational systems for interpreting molecular disease information and supporting treatment selection.

Personalized medicine and molecular oncology decision-support technology for clinicians and diagnostic laboratories.

• Clinical decision-support software

  CollabRx expert systems

  Cloud-based expert systems designed to support treatment selection for molecular diseases, particularly cancer. The systems used molecular disease models and associated knowledge bases to connect patient-specific biological findings with clinically relevant therapeutic approaches. Access was provided through software-as-a-service arrangements.

• Genomic data interpretation

  Molecular disease knowledge bases

  Structured and continuously updated bodies of scientific and clinical information that informed CollabRx’s molecular disease models. They were maintained with input from advisers and contributors connected with academic and medical institutions, with the aim of making rapidly expanding biological information more actionable for treatment decisions.

• 2015

  Merger with Medytox SolutionsM&A

  Background

  CollabRx was operating as a molecular-disease and personalized-medicine software business within the corporate history that followed its acquisition by Tegal Corporation.

  Action taken

  CollabRx merged with Medytox Solutions in October 2015.

  Aftermath

  The supplied sources do not document the subsequent status of the CollabRx name, products, or organization. The brand is therefore treated as defunct rather than active.

  Source

• 2012

  Tegal Corporation acquisitionM&A

  Background

  CollabRx had developed cloud-based expert systems for molecular disease treatment selection and was operating in the emerging personalized-medicine software sector.

  Action taken

  Tegal Corporation acquired CollabRx in July 2012.

  Aftermath

  CollabRx became part of Tegal Corporation. The available reference does not report transaction value, management changes, or detailed product consequences.

  Source

• 2015

  CollabRx merges with Medytox Solutions[1]CollabRxen.wikipedia.org

  M&A

  CollabRx was merged with Medytox Solutions in October 2015. The supplied reference does not provide further detail on the post-merger brand or operating structure.

• 2012

  Tegal Corporation acquires CollabRx[1]CollabRxen.wikipedia.org

  M&A

  Tegal Corporation acquired CollabRx in July 2012, bringing the molecular-disease decision-support company into its corporate structure.

1. 1CollabRxen.wikipedia.org